05), Body Part Naming (P < 0 05) and Memory (P < 0 05) Ton

05), Body Part Naming (P < 0.05) and Memory (P < 0.05). Tonsillar size correlated with OAHI (P < 0.01) and respiratory effort (P = 0.01) and respiratory airflow (P < 0.01). In cephalometry, the minimal distance from velum to posterior wall was shorter showing the shorter length

among snorers than non-snorers, 5.5 mm vs. 6.6 mm, respectively (P < 0.05). Recurrent upper respirataory infections (URIs) were common among the snoring than Oligomycin A order non-snoring children (P = 0.01). Children suffering recurrent URIs have more somatic complaints than children without recurrent URIs (P < 0.01).

Conclusions: Snoring children with apparently normal and/or no obstructive apnea, hypopnea, or marked SpO(2) desaturations appear to suffer impairment in neurocognitive and behavioral functions compared to non-snoring children. These snoring children did not reveal any major abnormalities of polysomnographic parameters, such as sleep-related breathing disorder, including partial upper airway obstruction. Polysomnographic parameters also correlated poorly with neurocognitive test results in these snoring children. The correlations between polysomnography and upper respiratory infections, with cephalometric and rhinometric

measures, were also poor. (C) 2011 Elsevier Ireland Ltd. All rights reserved.”
“Objectives: To compare (1) blood glucose and glycosylated click here hemoglobin (A1C) laboratory results and (2) longitudinal trends in blood glucose levels among veterans switched from one second-generation antipsychotic (SGA) P005091 to another.

Design: Retrospective, naturalistic, nonequivalent control group.

Setting: United States between April 1, 2003, and September 30, 2003.

Patients: 1,776 U. S. Veterans Health System beneficiaries living with schizophrenia-related

disorders switching (1) from olanzapine to another SGA, (2) to olanzapine from another SGA, and (3) among nonolanzapine SGAs.

Intervention: Data were retrieved from the laboratory results (LAR) database for a maximum of 180 days before and 365 days after the index date.

Main outcome measures: Mean blood glucose, A1C, and change in blood glucose.

Results: Blood glucose (36.0 mg/dL, paired t test((109)) = -4.87, P < 0.001) and A1C (1.0%, paired t((143)) = -4.84, P < 0.001) declined among veterans switched from olanzapine who were taking a blood glucose-lowering agent before the switch but was unchanged for those who were not. Adjusting for age, gender, and race, addition of the switch-type variables improved prediction of blood glucose change (F-ratio = 3.76, P = 0.03). Linear mixed-effects models confirmed that blood glucose levels declined for veterans switched from olanzapine with glucose dysregulation before the switch (Est(beta(2)-beta(1)) = -34.5 mg/dL, t((424)) = -5.05, P < 0.001).

Comments are closed.